Endothelins: A Family of Regulatory Peptides
State-of-the-Art Lecture Michael S. Simonson and Michael J. Dunn P eptide hormones are nearly ubiquitous in the body and play a major role in regulating homeostasis. Serving in an endocrine, paracrine, or neuroendocrine role, peptide hormones regulate such diverse physiological processes as cardiovascular hemodynamics; neurotransmission or neuromodulation; contractility of skeletal, cardiac, or smooth muscle; and control of cell proliferation. Peptide hormones also have been postulated to play a major pathophysiological role in such processes as atherosclerosis, hypertension, and perhaps even oncogenesis. 1 Thus, it comes as no surprise that the recent discovery of a new peptide hormone, endothelin (ET), has attracted much attention. 2 This review is intended to serve two functions: first, to provide an overview and bibliographic guide to ET biochemistry and physiology, and second, to outline what is known about the pathways of transmembrane signaling by which ET peptides elicit diverse biological actions. Limitations of space preclude exhaustive references; thus, the reader is directed to several recent reviews on specialized topics.
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The Endothelin Family of Regulatory Peptides Structure of Endothelin Isopeptides
The term "endothelin" refers to a family of acidic, 21-amino acid peptides found in at least four distinct isoforms: ET-1, ET-2, ET-3, and endothelin p (or vasoactive intestinal contractor). 6 - 7 ET isopeptides share sequence homology and a common design ( Figure 1 ). ET peptide chains are held in a hairpin loop configuration by two disulfide bonds between Cys-1 and Cys-15 and Cys-3 and Cys-11. Other notable features are the presence of polar, charged amino acid side chains within the hairpin loops (residues 6-10) and a hydrophobic C-terminus containing the aromatic indole side chain at Trp-21. Numerous structure and activity studies reveal that the hydrophobic C-terminus is requisite for bioactivity but that the hairpin loop configuration is also important. As with other peptides of similar size and configuration, elements of ET secondary and tertiary structure are likely to stabilize the interaction between ET and receptors at the plasma membrane interface. 8 Both in structure and bioactivity, ET peptides are closely related to sarafotoxins, peptide toxins isolated from venom of an Egyptian asp, Atractaspis engaddensis. 9 It seems likely that the two peptide families share a common evolutionary origin, and the high degree of sequence homology between ET and sarafotoxins suggests that ET genes have evolved under strong pressure to conserve the structure and function of mature ET peptides.
Synthesis of Endothelin
Relatively little is known about the synthetic pathway of ET peptides. Similar to other hormones and neurotransmitters, ET peptides arise through proteolytic processing of isopeptide-specific prohormones. 2 -3 PreproETs are large polypeptides (approximately 200 amino acids) with species-and isopeptide-specific differences in amino acid sequence. In addition, preproETs also contain a cysteine-rich, "ET-like" region (15 amino acids), but the activity and biological significance of this region remains unclear. Unlike other peptide hormones, processing of the preprohormone to the prohormone does not simply involve cleavage of the NH 2 -terminal signal sequence but also involves the loss of considerable sequences toward the COOH-terminus. Cotranslational and posttranslational modifications of the preproET species are unclear.
In cultured cells, preproET-1 is proteolytically cleaved to form a 38 (human) or 39 (porcine) amino acid proET-1.
-
6 Then a putative "endothelin-converting enzyme" cleaves at Trp-21-Val-22 of proET-1 to form the mature ET-1 peptide. To date, the endothelin-converting enzyme has been difficult to study, but characterization of this endopeptidase will have important implications for our understanding of how ET synthesis is regulated and for possible pharmacological blockade of ET synthesis.
It currently is unclear whether ET is stored in secretory granules or whether de novo synthesis is required for secretion. Immunostaining in the posterior pituitary suggests that ET is present in granules and that these granules are depleted on water deprivation. 
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These results suggest classical secretion of an endocrine peptide. In contrast, ET synthesis and release in other cell types appears to be dependent on differential regulation of ET gene expression. 311 The reason for this apparent paradox is unclear but may reflect different signaling modes (i.e., endocrine, neuroendocrine, paracrine) for ET peptides in different tissues. A variety of stimuli have been shown to increase ET synthesis, including Ca 2+ ionophores, phorbol esters, thrombin, transforming growth factor /3, endotoxin, fluid-mechanical shear stress, and anoxia (see References 3, 4, and 12 for review). ET appears to have a short t w in plasma, and the majority of circulating ET is cleared after one pass through the lungs, although it remains unclear whether ET is metabolically inactivated or removed by receptor-dependent endocytosis. 13 These findings and others have been cited as evidence that ET functions as a local hormone synthesized by specific endothelial or epithelial cells and acts in either a paracrine or autocrine mode on adjacent target cells. It remains possible, however, that under some conditions, ET released into the peripheral circulation might act as a classical endocrine hormone. Accumulating evidence suggests that ET synthesis is not limited to endothelial and epithelial cells; for example, glial cells 14 and glomerular mesangial cells 615 also synthesize endothelin.
Endothelin Is a Multigene Family Abundant evidence suggests that each ET isopeptide is encoded by a different gene. Genomic DNA blot analysis reveals single genes for preproET in the human, rat, and porcine genomes. - 17 The gene for human preproET-1 (approximately 6.8 kb) contains five exons and four introns; sequences encoding mature ET-1 are located in the second exon, and those for the 15-amino acid ET-like peptide are located within the third exon. 1116 In both the prepro-ET-1 and ET-3 genes, it seems likely that the second and third exon derive from a common progenitor exon, 16 leading Bloch and coworkers 17 to hypothesize that the ET-1, ET-2, and ET-3 genes evolved by gene duplication events. The promoter region of the preproET-1 gene contains a typical eukaryotic TATA box and CAAT sequence. Moreover, 5' upstream putative cis-acting sequences exist for activating protein 1, nuclear factor 1, and acute phase response trans-acting factors, although transcriptional regulation via these sequences has yet to be demonstrated experimentally. Functional analysis of the prepro-ET-1 gene promoter by Lee and coworkers 18 reveals two promoter regions, located at sequence -148 to -117 and -117 to -98, that appear to be necessary for transcriptional activation. In heterologous promoter constructs using a DNA fragment containing these two regions, this sequence acted in a positive and endothelial cell-specific fashion. 18 Further analysis of this promoter should reveal how ET peptides are differentially expressed only in specific tissues. It also is important to note that analysis of the 3' noncoding region of preproET-1 mRNA reveals AU-rich sequences thought to decrease mRNA stability in the cytoplasm. Indeed, the t^ of preproET-1 mRNA is short (approximately 15 minutes), and the mRNA transcripts are superinduced by cycloheximide. 11 Thus, preproET-1 gene expression appears to be regulated at several levels, including transcriptional control and mRNA stability. ET first evokes a transient depressor phase, which has been attributed to endothelial release of prostacyclin and endothelium-derived relaxing factor, followed by a marked and extended pressor phase. The duration of the pressor phase is longer than with any constrictor peptide yet tested, and 1-3 hours typically are required for mean arterial pressure to return to baseline levels. As expected, ET is a potent contractile agent for numerous vascular smooth muscle strips in vitro. 4 Much attention has focused on the ability of ET to regulate cardiac function. ET exerts a strong, dose-dependent positive inotropic effect on the myocardium. 22 - 23 Blockers of /3-adrenergic, a-adrenergic, serotonergic, and histaminergic receptors and pretreatment with indomethacin failed to inhibit the inotropic action of ET, suggesting a direct effect on the myocardium. ET appears to augment inotropic activity by elevating cytosolic free [Ca 2+ ], either by increasing the opening probability of L-type, voltage-activated Ca 2+ channels or by increasing activity of the phosphoinositide cascade with subsequent release of intracellular Ca 2+ from the inositol 1,4,5-trisphosphate (Ins[l,4,5]P 3 )-sensitive intracellular stores.
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. 24 In the guinea pig right atria, ET also elicits a positive chronotropic effect, 25 but the mechanism involved is not understood. The coronary arteries also are an important site of action for ET peptides. Coronary arteries have a high density of binding sites for ET-1 and ET-2, 4 and infusion of these peptides causes intense vasoconstriction leading in some cases to lethal myocardial ischemia.
-
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ET has been postulated to play a role in cardiovascular disease. Plasma levels of ET are increased in myocardial infarction, cardiogenic shock, congestive heart failure, and hypertension.
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- 29 Moreover, ET has been suggested to contribute to the development of postischemic myocardial injury and hypertension.
Endocrine Effects of EndotheUn
In addition to having primary effects as a potent peptide hormone, ET also exerts indirect actions through interactions with diverse endocrine systems. Infusion of ET into humans and dogs causes a rapid increase in the plasma levels of atrial natriuretic factor, renin, aldosterone, and circulating catecholamines. 19 - 21 In most studies, ET increases epinephrine more than norepinephrine, which suggests that sympathetic stimulation of the adrenal medulla accounts for the increased circulating catecholamine levels. It remains uncertain whether the ability of ET to increase the level of circulating hormones is a direct effect or is secondary to the hemodynamic effects of ET. However, the finding that renin and aldosterone, which would preserve extracellular fluid volume and increase blood pressure, increase after infusion of a vasoconstrictor peptide suggests mechanisms other than secondary effects due to the increase in arterial pressure. In addition, in cultured bovine adrenal cortical cells, ET enhances adrenocorticotropin-stimulated aldosterone. 30 
EndotheUn as a Neuropeptide
ET also appears to regulate synaptic transmission in both the central and peripheral nervous systems by acting as a neuromodulator and perhaps even as a neurotransmitter.
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- 33 For example, ET modulates the release of catecholamines from sympathetic termini and from chromaffin cells in the adrenal medulla. There also is indirect evidence that ET functions as a neurotransmitter in the central nervous system. 32 Several observations suggest that ET functions as a neuropeptide regulating the hypothalamic-pituitary axis. ET-1 stimulates the release of luteinizing hormone and follicle-stimulating hormone from cells of the anterior pituitary leased by water deprivation, suggesting secretion of ET by physiological stimuli. Thus, like the classical hormones of the posterior pituitary, arginine vasopressin and oxytocin, ET appears to be synthesized in the hypothalamus, transported to the posterior pituitary, and secreted upon appropriate neuroendocrine stimuli. The neural inputs controlling ET release and the target hormones remain to be characterized.
Endothelin Is a Potent Renal Peptide
The intrarenal effects of ET include dramatic reductions in renal blood flow, with efferent glomerular arteriolar constriction being greater than that of afferent glomerular arterioles.
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- 35 Contraction of the arcuate and interlobular arteries contributes to the decline in renal blood flow. Glomerular filtration rate also decreases both in response to the reductions in flow and as a result of decreases in the glomerular ultrafiltration coefficient. ET also causes marked reductions in urine volume and either modest increases 20 or marked reductions in Na + excretion,
depending on the dose of ET administered. ET actions on sodium handling are complex and include reductions in the filtered load of sodium to tubular reabsorptive sites and attenuation of Na + ,K + -ATPase activity in the medullary collecting duct via a prostaglandin E^-dependent mechanism. 36 It perhaps is surprising that ET increases urine flow rate and free water clearance despite the dramatic decline in glomerular filtration rate and renal blood flow. 19 -35 One possible explanation is that ET increases water excretion by inhibiting the effect of arginine vasopressin to stimulate water permeability in collecting ducts, 37 but this hypothesis remains to be tested. There also is evidence that ET contributes to the pathogenesis of cyclosporine nephrotoxicity, glomerular inflammation, and postischemic renal injury (see Reference 38 for review). For example, cyclosporine increases ET synthesis from the damaged endothelium, and infusion of neutralizing antibodies against ET prevents the renal vasoconstriction and glomerular dysfunction associated with cyclosporine-induced renal disease. 39 Because hypoxia is a potent stimulus of ET release, Firth et al 40 suggested that ET mediates hemodynamically induced acute renal failure. Support for this view comes from the work of Kon and coworkers, 41 who showed in a model of postischemic renal injury that ET-neutralizing antibodies reverse the reduction in single nephron glomerular filtration rate and renal blood flow. Thus, ET released by damaged endothelium or mesangial cells might contribute to the hypoperfusion and hypofiltration seen in postischemic renal injury.
Other Biological Actions
Other biological actions of ET remain poorly understood. ET contracts numerous nonvascular smooth muscle preparations from the gastrointestinal tract, trachea, lung, and bladder. 48 and of the c-fos and c-myc proto-oncogenes in vascular smooth muscle, 3T3 fibroblasts, and mesangial cells. 43 
"
47 The mechanisms by which ET regulates gene expression remain unknown; however, the finding that ET evokes the phosphoinositide cascade (see below) raises the possibility that ET upregulates inducible enhancers with phorbol ester-responsive or Ca 2+ -responsive elements.
Regulation of Transmembrane Signaling
From the preceding discussion, it is clear that ET peptides are involved in a large array of biological functions. How can ET peptides perform these diverse actions? Abundant evidence suggests that ET initially activates a transduction process involving a cell-surface receptor, a coupling G protein, and phospholipase C. The consequences of activating this ubiquitous signal transduction process is outlined below.
Receptors for Endothelin
ET binds to specific plasma membrane receptors that are widely distributed in the lung, kidney, heart, intestine, adrenal gland, eye, and nervous system. gial cells. For example, ET-1 causes a dose-dependent increase in phosphatidylinositol turnover measured at 15 minutes in the presence of L i d Activation of phospholipase C by ET produces at least two second messengers: 1) the neutral diacylglycerol, which remains within the plane of the plasma membrane and activates protein kinase C (PKC); and 2) the watersoluble Ins(l,4^)P 3 , which diffuses and binds to a receptor-gated Ca 2+ channel to release Ca 2+ from specialized stores within the endoplasmic reticulum, or calciosome. ET-1 also elevates the cytosolic concentration of another inositol phosphate isomer, Ins(l,3,4^)P 4 , which appears to contribute to the complex patterns of Ca 2+ signaling by ET. Activation of the phosphoinositide cascade by ET peptides is thought to mediate many of the biological actions of ET, including contraction by pharmacomechanical coupling, secretion, and perhaps mitogenesis. 5 Although we focus here primarily on Ca 2+ signaling, activation of PKC by diacylgfycerol is thought to mediate many of the biological actions after ET receptor activation (see References 3 and 5).
Ca
2+ Signaling by Endothelin Peptides
Using mesangial cells loaded with the fluorescent Ca 2+ indicator fura-2, we have investigated Ca 2+ signaling by ET peptides. ]i) consisting of a rapid (2-5 seconds) spike increase followed by a lesser but sustained phase (Figure 2) . The sustained phase of [Ca 2+ ]j is especially pronounced, and in some coverslips [Ca 2+ ] ( returned to basal levels only after 20 minutes. ET-1-induced Ca 2+ signaling requires conversion of proET-1 to ET-1, suggesting that in proET-1, the mature ET-1 peptide is constrained in an inactive conformation. 52 Although similar results have been observed for all ET isopeptides, the increment in [Ca 2+ ], is dose-dependent, with ET-2=ET-l>sarafotoxin S6b>ET-3. Thus, ET isopeptides and S6b evoke similar elevations of [Ca 2+ ]i in mesangial cells but with dissimilar potencies and kinetics.
Two distinct but interdependent mechanisms contribute to ET-induced increments in [Ca 2+ ],. ET releases Ca 2+ from intracellular stores, presumably through the action of Ins(l,4,5)P 3 to gate an intracellular Ca 2+ channel, but ET also increases influx of extracellular Ca 2+ into the cytosol. These two mechanisms (intracellular release and extracellular influx) work in concert to produce an integrated Ca 2+ signal. In mesangial cells, for example, the spike increase in [Ca 2+ ]| results from both intracellular release of Ca 2+ and extracellular influx of Ca 2+ , whereas the sustained phase of [Ca 2+ ], depends on extracellular influx (Figure 2) . Influx of extracellular Ca 2+ occurs through voltage-gated channels or through receptorgated, voltage-independent channels. Our experiments in cultured rat and human mesangial cells demonstrate that ET promotes Ca 2+ entry by receptor-gated Ca 2+ channels and that voltage-gated, dihydropyridine-sensitive channels play little or no ], increase stimulated by the subsequent, equimolar addition of any other isopeptide. 52^3 ET-mediated desensitization persists in cells depleted of PKC, suggesting that this adaptive response is independent of PKC. It is important to note that many investigators report complex, partially reversible binding of ET to its receptor; thus, continued receptor occupancy might account for some of the desensitization observed in our studies. However, it also is likely that other mechanisms such as phosphorylation of the ET receptor by homologous or heterologous pathways might contribute to densensitization induced by ET ligands.
In preliminary experiments, we have characterized a third negative-feedback mechanism to regulate Ca 2+ signaling by ET. Using an inhibitor of the endoplasmic reticular Ca 2+ -ATPase, 2,5-Di-(tert-butyl)-l,4-benzohydroquinone (tBuBHQ), we have identified a Ca 2+ efflux pathway stimulated by ET. 52 tBuBHQ causes a sustained increase in [Ca 2+ ], by preventing reuptake into intracellular stores. 57 -mobilizing hormones.
In summary, ET is an important family of regulatory peptides synthesized by endothelial and epithelial cells, neurons, and perhaps specific connective tissue cells in vivo. ET synthesis and release is increased by a variety of stimuli, including Ca 2+ ionophores, phorbol esters, thrombin, transforming growth factor /3, endotoxin, fluid-mechanical shear stress, and anoxia. ET appears to function mostly as a paracrine or autocrine hormone; however, ET also might function as a classical endocrine hormone as well. ET has numerous biological activities relating to vasoconstriction and smooth muscle contraction; cardiac, pulmonary, and renal function; neurotransmission; and mitogenesis and tissue remodeling. Although numerous signal transduction pathways are activated by ET, it is well-documented that induction of the phosphoinositide cascade mediates many of the actions of ET. ET also invokes complex mechanisms to stimulate a tightly regulated Ca 2+ signaling system. 
